207 related articles for article (PubMed ID: 15686976)
1. Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate.
Pu R; Coleman J; Coisman J; Sato E; Tanabe T; Arai M; Yamamoto JK
J Feline Med Surg; 2005 Feb; 7(1):65-70. PubMed ID: 15686976
[TBL] [Abstract][Full Text] [Related]
2. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats.
Kusuhara H; Hohdatsu T; Okumura M; Sato K; Suzuki Y; Motokawa K; Gemma T; Watanabe R; Huang C; Arai S; Koyama H
Vet Microbiol; 2005 Jul; 108(3-4):155-65. PubMed ID: 15899558
[TBL] [Abstract][Full Text] [Related]
3. Serological differentiation of FIV-infected cats from dual-subtype feline immunodeficiency virus vaccine (Fel-O-Vax FIV) inoculated cats.
Kusuhara H; Hohdatsu T; Seta T; Nemoto K; Motokawa K; Gemma T; Watanabe R; Huang C; Arai S; Koyama H
Vet Microbiol; 2007 Mar; 120(3-4):217-25. PubMed ID: 17141431
[TBL] [Abstract][Full Text] [Related]
4. Sequence variation of the feline immunodeficiency virus genome and its clinical relevance.
Stickney AL; Dunowska M; Cave NJ
Vet Rec; 2013 Jun; 172(23):607-14. PubMed ID: 23749359
[TBL] [Abstract][Full Text] [Related]
5. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
[TBL] [Abstract][Full Text] [Related]
6. Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine.
Sahay B; Yamamoto JK
Viruses; 2018 May; 10(5):. PubMed ID: 29789450
[TBL] [Abstract][Full Text] [Related]
7. Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies.
Coleman JK; Pu R; Martin MM; Noon-Song EN; Zwijnenberg R; Yamamoto JK
Vaccine; 2014 Feb; 32(6):746-54. PubMed ID: 23800540
[TBL] [Abstract][Full Text] [Related]
8. Lack of protection against feline immunodeficiency virus infection among domestic cats in New Zealand vaccinated with the Fel-O-Vax® FIV vaccine.
Stickney A; Ghosh S; Cave NJ; Dunowska M
Vet Microbiol; 2020 Nov; 250():108865. PubMed ID: 33045631
[TBL] [Abstract][Full Text] [Related]
9. Dual-subtype feline immunodeficiency virus vaccine provides 12 months of protective immunity against heterologous challenge.
Huang C; Conlee D; Gill M; Chu HJ
J Feline Med Surg; 2010 Jun; 12(6):451-7. PubMed ID: 20167521
[TBL] [Abstract][Full Text] [Related]
10. Feline immunodeficiency virus model for designing HIV/AIDS vaccines.
Yamamoto JK; Sanou MP; Abbott JR; Coleman JK
Curr HIV Res; 2010 Jan; 8(1):14-25. PubMed ID: 20210778
[TBL] [Abstract][Full Text] [Related]
11. The development of a vaccine against feline immunodeficiency virus.
Hosie MJ
Br Vet J; 1994; 150(1):25-39. PubMed ID: 8025833
[TBL] [Abstract][Full Text] [Related]
12. Lessons from the cat: development of vaccines against lentiviruses.
Dunham SP
Vet Immunol Immunopathol; 2006 Jul; 112(1-2):67-77. PubMed ID: 16678276
[TBL] [Abstract][Full Text] [Related]
13. Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus.
Dunham SP; Bruce J; Klein D; Flynn JN; Golder MC; MacDonald S; Jarrett O; Neil JC
Vaccine; 2006 Nov; 24(49-50):7095-108. PubMed ID: 17049683
[TBL] [Abstract][Full Text] [Related]
14. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates.
Pu R; Coleman J; Omori M; Arai M; Hohdatsu T; Huang C; Tanabe T; Yamamoto JK
AIDS; 2001 Jul; 15(10):1225-37. PubMed ID: 11426067
[TBL] [Abstract][Full Text] [Related]
15. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
Stevens R; Lavoy A; Nordone S; Burkhard M; Dean GA
Vaccine; 2005 Feb; 23(12):1479-90. PubMed ID: 15670884
[TBL] [Abstract][Full Text] [Related]
16. Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax
Westman M; Yang D; Green J; Norris J; Malik R; Parr YA; McDonald M; Hosie MJ; VandeWoude S; Miller C
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809232
[TBL] [Abstract][Full Text] [Related]
17. Experimental vaccine protection against feline immunodeficiency virus.
Yamamoto JK; Okuda T; Ackley CD; Louie H; Pembroke E; Zochlinski H; Munn RJ; Gardner MB
AIDS Res Hum Retroviruses; 1991 Nov; 7(11):911-22. PubMed ID: 1662057
[TBL] [Abstract][Full Text] [Related]
18. Mechanism(s) of FIV vaccine protection.
Pu R; Tellier MC; Yamamoto JK
Leukemia; 1997 Apr; 11 Suppl 3():98-101. PubMed ID: 9209311
[TBL] [Abstract][Full Text] [Related]
19. Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine.
Omori M; Pu R; Tanabe T; Hou W; Coleman JK; Arai M; Yamamoto JK
Vaccine; 2004 Dec; 23(3):386-98. PubMed ID: 15530685
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a feline immunodeficiency virus vaccine.
Huang C; Conlee D; Loop J; Champ D; Gill M; Chu HJ
Anim Health Res Rev; 2004 Dec; 5(2):295-300. PubMed ID: 15984343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]